Given that we found the pluripotency factors NANOG, SOX2, and OCT4 as potential regulators of mesenchymal plasticity, we next aimed to investigate whether their expression predicts clinical variables that relate to therapy resistance and increased tumor cell mobility in EAC. This evidence concerns the gene SOX2 and neoplasm.